Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM P/E Multiple | 31.1x - 34.4x | 32.7x |
Selected Fwd P/E Multiple | 10.7x - 11.9x | 11.3x |
Fair Value | €23.54 - €26.02 | €24.78 |
Upside | -13.5% - -4.4% | -8.9% |
Benchmarks | - | Full Ticker |
Collegium Pharmaceutical, Inc. | - | NasdaqGS:COLL |
Aquestive Therapeutics, Inc. | - | NasdaqGM:AQST |
Assertio Holdings, Inc. | - | NasdaqCM:ASRT |
Cumberland Pharmaceuticals Inc. | - | NasdaqGS:CPIX |
Amphastar Pharmaceuticals, Inc. | - | NasdaqGS:AMPH |
Supernus Pharmaceuticals, Inc. | - | DB:S49 |
- | - | - |
Select Price / LTM EPS Ratio | ||||||||
Benchmark Companies | ||||||||
COLL | AQST | ASRT | CPIX | AMPH | S49 | |||
NasdaqGS:COLL | NasdaqGM:AQST | NasdaqCM:ASRT | NasdaqGS:CPIX | NasdaqGS:AMPH | DB:S49 | |||
Historical Net Income Growth | ||||||||
5Y CAGR | NM- | NM- | NM- | NM- | 26.7% | -8.2% | ||
3Y CAGR | -1.1% | NM- | NM- | NM- | 36.9% | 11.4% | ||
Latest Twelve Months | -53.0% | -88.6% | 90.8% | 61.1% | -8.4% | 499.2% | ||
Historical Net Income Profit Margin | ||||||||
5 Year Average Margin | 8.7% | -93.3% | -55.2% | -12.8% | 14.6% | 11.2% | ||
Prior Fiscal Year | 8.5% | -15.6% | -218.3% | -15.9% | 21.3% | 0.2% | ||
Latest Fiscal Year | 11.0% | -76.7% | -17.3% | -17.1% | 21.8% | 11.2% | ||
Latest Twelve Months | 6.6% | -100.0% | -25.7% | -8.0% | 19.4% | 9.3% | ||
Current Trading Multiples | ||||||||
EV / LTM EBITDA | 4.8x | -8.4x | -25.5x | 27.9x | 6.1x | 11.3x | ||
Price / LTM Sales | 1.5x | 6.8x | 0.5x | 1.1x | 1.5x | 3.0x | ||
LTM P/E Ratio | 22.2x | -6.8x | -2.0x | -14.4x | 7.7x | 32.3x | ||
Low | Mid | High | ||||||
Benchmark LTM P/E Ratio | -14.4x | -2.0x | 22.2x | |||||
Historical LTM P/E Ratio | 10.3x | 33.4x | 61.7x | |||||
Selected P/E Multiple | 31.1x | 32.7x | 34.4x | |||||
(x) LTM Net Income | 62 | 62 | 62 | |||||
(=) Equity Value | 1,926 | 2,027 | 2,129 | |||||
(/) Shares Outstanding | 62.6 | 62.6 | 62.6 | |||||
Implied Value Range | 30.76 | 32.38 | 34.00 | |||||
FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
Implied Value Range (Trading Cur) | 26.11 | 27.48 | 28.86 | 27.20 | ||||
Upside / (Downside) | -4.0% | 1.0% | 6.1% |
Equity Value | |||||||
Benchmark Companies | |||||||
(in millions) | COLL | AQST | ASRT | CPIX | AMPH | S49 | |
Value of Common Equity | 976 | 369 | 63 | 47 | 1,094 | 2,007 | |
(/) Shares Outstanding | 32.1 | 99.3 | 95.8 | 15.0 | 47.1 | 62.6 | |
Implied Stock Price | 30.35 | 3.72 | 0.65 | 3.15 | 23.20 | 32.05 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.18 | |
Implied Stock Price (Trading Cur) | 30.35 | 3.72 | 0.65 | 3.15 | 23.20 | 27.20 | |
Trading Currency | USD | USD | USD | USD | USD | EUR | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.18 |
The video below provides an overview of the key benefits to help you get the most out of InvestingPro.